CAS: 15421-84-8; N,N-Diethyl-5-Methyl-[1,2,4]Triazolo[1,5-A]Pyrimidin-7-Amine

该化合物是一种医药化合物,主要用作血管药剂,被归类为光滑肌肉放松剂,众所周知,它能够通过涂层血管改善血液流动,这可能有助于治疗边缘血管疾病和某些种类的心血管病等疾病.创伤性紧张症的化学结构包括一种子宫颈病,有助于其药理活动.它在水中表现出中等溶解性,一般是口服的.行动机制包括抑制板板块的聚集和血管光滑肌肉音的调节,这有助于减少血压和增加循环.创伤性创伤一般是良好的,但与许多药物一样,它可能具有副作用,包括头晕或胃肠扰动.它的安全性和功效在各种临床研究中得到了评估,在特定治疗环境中成为了一种相关的选择.与任何药物一样,必须在医疗监督下使用Trapidil,以确保对可能的相互作用或不利影响进行适当的治疗和监测.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号35523-67-2 4-methyl-1,5,7,... | CAS号24415-66-5 7-氯-5-甲基-1,2,4-... | CAS号109-89-7 二乙胺

合成工艺路线路线简述

    📜4,7-Dihydro-5-Methyl-7-Oxo[1,2,4]Triazolo[1,5-A]Pyrimidine置于三氯氧磷体系中,化学反应生成曲匹地尔
    参考文献:Kano; Makisumi,Chemical And Pharmaceutical Bulletin,1958,Vol. 6,P. 583,585
    标题:Kano; Makisumi,Chemical And Pharmaceutical Bulletin,1958,Vol. 6,P. 583,585

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:WO-9614060-A1
    优先权日:1994-11-04
    标题 :Use of receptor agonists to stimulate superoxide dismutase activity
    发明人:MARKLUND STEFAN L; STRAALIN PONTUS
    权利人:MARKLUND STEFAN L; STRAALIN PONTUS
    摘要:The present invention relates to the use of a substance for the manufacture of a composition for stimulating the release of EC-SOD from cells or stimulating the synthesis of EC-SOD in cells. In particular, the invention relates to the use of a substance for the manufacture of a composition for prophylaxis or treatment of a disease or disorder connected with the presence or formation of superoxide radicals and other toxic intermediates derived from the superoxide radical. Further, the invention relates to a method for determining the effect of a substance with respect to stimulating the release of EC-SOD from cells or stimulating the synthesis of EC-SOD in cells and to substances which have been selected by said method. Within the scope of the invention is a method of preventing, diminishing, controlling or inhibiting a disease or disorder connected with the presence or formation of superoxide radicals and other toxic intermediates derived from the superoxide radical in a patient who has been established to have a high risk of developing a such disease or disorder, or who has developed a such disease or disorder, the method comprising administering an effective amount of a substance which is capable of stimulating the release of EC-SOD from cells or stimulating the synthesis of EC-SOD in cells.

    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-2011318421-A1
    优先权日:2010-06-24
    标 题:Surface functionalized ceramic nanoparticles
    发明人:PARSONAGE EDWARD
    权利人:PARSONAGE EDWARD
    摘要:The present disclosure is directed to surface functionalized ceramic nanoparticles. The method for producing the surface functionalized ceramic nanoparticles generally includes at least four distinct steps: 1) synthesis of an amphiphilic surfactant having the desired surface functionality, 2) formation of mixed solvent microstructured solution with the surfactant, 3) synthesis of the desired ceramic within the microstructured solution, and 4) chemical attachment of the surfactant to the ceramic nanoparticle. The composition of the surface functionalized nanoparticle comprises a lipophilic component, a hydrophilic component, a chelating agent and a ceramic forming component.

    专利号:EP-1789107-B1
    优先权日:2004-08-30
    标题 :Medical stent provided with inhibitors of atp synthesis
    发明人:POPOWSKI YOURI
    权利人:INTERSTITIAL THERAPEUTICS
    摘要:The present invention relates to a stent provided with a composition comprising at least one type of inhibitor of ATP synthesis optionally together with at least one inhibitor of the pentose phosphate pathway (PPP) for use in treating stenosis and preventing restenosis in vascular ducts, and for use in treating cancerous tumours present in ducts, resectioned cavities and scars, and for use in treating any disorder arising from the proliferation of cells in ducts or cavities.

    专利号:US-10814013-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Liu M, Sun Q, Wang Q, Wang X, Lin P, Yang M, Yan Y. Effect of trapidil in myocardial ischemia-reperfusion injury in rabbit. Indian J Pharmacol. 2014 Mar-Apr;46(2):207-10. doi: 10.4103/0253-7613.129320.
    2: Kim SD, Kim HN, Lee JH, Jin WJ, Hwang SJ, Kim HH, Ha H, Lee ZH. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice. Biochem Pharmacol. 2013 Sep 15;86(6):782-90. doi: 10.1016/j.bcp.2013.07.015. Epub 2013 Aug 6. doi: 10.1016/j.curtheres.2013.04.002.
    4: Watanabe I, Okumura Y, Nagashima K, Kofune M, Ohkubo K, Mano H, Sonoda K, Kasamaki Y, Hirayama A. Effects of the antianginal drug trapidil on atrioventricular conduction disturbances during acute myocardial ischemia. Int Heart J. 2012;53(3):187-92. doi: 10.3109/0886022X.2010.501933. doi: 10.1007/s00345-008-0323-7. Epub 2008 Sep 2. Trapidil is as effective as isosorbide-dinitrate for treating stable angina pectoris: a multinational, multicenter, double-blind, randomized study. Clin Res Cardiol. 2006 Apr;95(4):217-23. Epub 2006 Mar 22. Epub 2007 Aug 13. German.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知